Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

Core Insights - Ginkgo Bioworks reported a total revenue of $33 million for Q4 2025, a decrease of 24% compared to $44 million in Q4 2024, with Biosecurity revenue at $7 million and Cell Engineering revenue at $26 million, down 30% and 26% respectively [1] - For the full year 2025, total revenue was $170 million, down 25% from $227 million in 2024, primarily due to a shift from early-stage customers to larger enterprise clients [1] - The company announced a strategic focus on autonomous labs and plans to divest its non-core biosecurity business, which will operate as a standalone entity [1] Financial Performance - Q4 2025 total revenue was $33 million, down from $44 million in Q4 2024, with Biosecurity revenue decreasing from $9 million to $7 million and Cell Engineering revenue decreasing from $35 million to $26 million [1] - Full year 2025 total revenue was $170 million, down from $227 million in 2024, with Cell Engineering revenue at $133 million, down from $174 million, and Biosecurity revenue at $37 million, down from $53 million [1] - The company ended 2025 with $423 million in cash, cash equivalents, and marketable securities, indicating a strong cash position despite the revenue decline [1] Strategic Focus - Ginkgo plans to invest in autonomous labs, aiming to demonstrate capabilities by consolidating its R&D services into a single large autonomous lab [1] - The company is expanding its frontier autonomous lab in Boston to include over 50 Reconfigurable Automation Carts (RACs), with an additional 50 expected by year-end [1] - Ginkgo has secured a $47 million contract for a 97-instrument autonomous lab and has collaborated with OpenAI to improve experiment design, achieving a 40% improvement in Cell-Free Protein Synthesis [1] Business Divestiture - Ginkgo has reached an agreement to sell its biosecurity business to a consortium of investors, allowing it to operate as a standalone entity while Ginkgo retains a minority equity position [1] - This divestiture is expected to provide the biosecurity business with greater flexibility and resources for growth, while Ginkgo can focus its investments on the autonomous labs business [1] 2026 Outlook - Ginkgo anticipates a total cash burn of $(150) million to $(125) million in 2026 as it continues to invest in its autonomous labs [1]